Clinical Benefit of Long-Term Disease Control with Pomalidomide and Dexamethasone in Relapsed/Refractory Multiple Myeloma Patients

Background: We retrospectively analysed relapsed/refractory MM (RRMM) patients treated with pomalidomide and dexamethasone (PomaD) either in real life, or previously enrolled in an interventional (STRATUS, MM-010) or currently enrolled in an observational study (MM-015) to provide further insights o...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:J Clin Med
Autors principals: Parisi, Marina Silvia, Leotta, Salvatore, Romano, Alessandra, Del Fabro, Vittorio, Martino, Enrica Antonia, Calafiore, Valeria, Giubbolini, Rachele, Markovic, Uros, Leotta, Valerio, Di Giorgio, Mary Ann, Tibullo, Daniele, Di Raimondo, Francesco, Conticello, Concetta
Format: Artigo
Idioma:Inglês
Publicat: MDPI 2019
Matèries:
Article
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC6832641/
https://ncbi.nlm.nih.gov/pubmed/31623097
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3390/jcm8101695
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars